Form D · Biotechnology
Lirum Therapeutics, Inc.
New York, NY · CIK 0001965411
Offering snapshot reported Feb 23, 2023 · SEC filing
- Reported sold
- $6.3M Offering amount: $10M
- Investors reported
- 53 Form D · investor count
- Minimum accepted
- $5K Reported outside-investor minimum
- First sale
- Feb 8, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 23, 2023 | Initial | $6,300,000 | No comparison | 53 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $359K
- Finders' fees
- $0
- Form D file number
- 021-474079
In addition to cash fees equaling $359,240 Think Equity received Placement Agent Warrants exercisable for 504,000 shares of Lirum common stock.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| ThinkEquity LLC | 20996 |
Source: Form D, filed Feb 23, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ivan Bergstein | Director |
| Kenneth Hoberman | Director, Executive |
| Daniel Hume | Director |
| Mark Sard | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
590 Madison Avenue 21 St Floor
New York, NY, 10022
New York, NY, 10022